SCOPE, NCT04079166: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study) |
|
|
| Recruiting | 2 | 130 | Europe | SCIB1 or iSCIB1+ DNA vaccine | Scancell Ltd | Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV | 01/26 | 01/26 | | |